These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26131840)

  • 1. Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
    Trueba-Arguiñarena FJ; de Prado-Otero DS; Poves-Alvarez R
    Medicine (Baltimore); 2015 Jul; 94(26):e946. PubMed ID: 26131840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
    Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
    Hiyoshi M; Nanashima A; Wada T; Tsuchimochi Y; Hamada T; Yano K; Imamura N; Fujii Y
    Clin J Gastroenterol; 2017 Dec; 10(6):551-557. PubMed ID: 29086227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
    Hubault M; Faure R; Walter T; Forestier J; Lombard-Bohas C; Pivot C
    Bull Cancer; 2015 May; 102(5):403-4. PubMed ID: 25866372
    [No Abstract]   [Full Text] [Related]  

  • 7. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
    Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
    N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
    John P; Butler H; Saif MW
    Anticancer Res; 2014 Dec; 34(12):7267-70. PubMed ID: 25503159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant
    Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
    Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
    Miyashita T; Tajima H; Makino I; Okazaki M; Yamaguchi T; Ohbatake Y; Nakanuma S; Hayashi H; Takamura H; Ninomiya I; Fushida S; Kishimoto K; Harmon JW; Ohta T
    Anticancer Res; 2018 Jan; 38(1):337-343. PubMed ID: 29277792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
    Bhutiani N; Agle S; Li Y; Li S; Martin RC
    J Surg Oncol; 2016 Aug; 114(2):181-6. PubMed ID: 27393627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
    Belfiore MP; Ronza FM; Romano F; Ianniello GP; De Lucia G; Gallo C; Marsicano C; Di Gennaro TL; Belfiore G
    Int J Surg; 2015 Sep; 21 Suppl 1():S34-9. PubMed ID: 26118600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
    Bhutiani N; Li Y; Zheng Q; Pandit H; Shi X; Chen Y; Yu Y; Pulliam ZR; Tan M; Martin RCG
    Ann Surg Oncol; 2020 Oct; 27(11):4348-4359. PubMed ID: 32681477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
    Yalcin S; Dane F; Oksuzoglu B; Ozdemir NY; Isikdogan A; Ozkan M; Demirag GG; Coskun HS; Karabulut B; Evrensel T; Ustaoglu MA; Ozdemir F; Turna H; Yavuzsen T; Aykan F; Sevinc A; Akbulut H; Yuce D; Hayran M; Kilickap S
    BMC Cancer; 2020 Mar; 20(1):259. PubMed ID: 32228512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
    Borazanci E; Von Hoff DD
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):739-47. PubMed ID: 24882381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
    Huang KW; Yang PC; Pua U; Kim MD; Li SP; Qiu YD; Song TQ; Liang PC
    J Surg Oncol; 2018 Jul; 118(1):31-36. PubMed ID: 29878378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
    Vicente E; Quijano Y; Ielpo B; Duran H
    Surg Oncol; 2017 Sep; 26(3):276-277. PubMed ID: 29804945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
    Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
    Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.